
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is a leader in the oncology-focused biopharmaceutical market due to its diverse portfolio and strong financial standing. With the success of their top BTK inhibitor, Brukinsa, and promising treatments for solid tumors in their pipeline, the company is well positioned for continued growth. Experts view Brukinsa as a top choice for treating CLL, and with a projected peak sales of $7.1B, BeOne Medicines has the potential to deliver strong returns for investors. As the company remains committed to innovation and sustainability, it presents a promising investment opportunity with a Buy recommendation and $400 price target.
Bears say
BeOne Medicines is currently an oncology-focused biopharmaceutical company, but faces significant challenges in maintaining its current position and driving future growth. With Brukinsa being its primary revenue driver, any decline in sales or setbacks in pipeline programs could have a significant impact on the company's financials. Additionally, the company's reliance on the success of early-stage assets like sonrotoclax and BTK CDAC pose a risk, as delays or failures could hinder their future commercialization. There is also the risk of competition increasing, particularly for Brukinsa, from other companies in the crowded heme-onc space. Lastly, the company faces a potential geopolitical risk due to its Chinese roots, which could negatively impact investor sentiment.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares